Nanobiotix SA
NBTX
View Detailed Chart
19.870USD
+0.200+1.02%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
958.02MMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.02%
5 Days
-4.79%
1 Month
-33.57%
6 Months
+482.70%
Year to Date
+592.33%
1 Year
+373.10%
View Detailed Chart
TradingKey Stock Score of Nanobiotix SA
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nanobiotix SA's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Strong Buy
Current Rating
17.400
Target Price
-12.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Nanobiotix SA Highlights
StrengthsRisks
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Growing
The company is in a growing phase, with the latest annual income totaling USD -10.69M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD -10.69M.
Undervalued
The company’s latest PE is -10.83, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.65M shares, decreasing 42.25% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 0.00 shares of this stock.
Nanobiotix SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Nanobiotix SA Info
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Ticker SymbolNBTX
CompanyNanobiotix SA
CEODr. Laurent Levy, Ph.D.
Websitehttps://www.nanobiotix.com
Related Instruments
-1.43%
-0.22%
+0.06%
+0.97%
-0.17%
+0.59%
+1.46%
-1.78%
-3.70%
+0.06%
+0.34%
-0.77%
-1.63%
+0.16%
-1.00%
+0.58%
0.00%
+1.65%
+0.50%
+0.57%Popular Symbols
